8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2015

Eagle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36306	20-8179278
(State or other jurisdiction	(Commission File Number)	(IRS Employer Identification No.)
of incorporation)

50 Tice Boulevard, Suite 315 Woodcliff Lake, NJ	07677
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (201) 326-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01Other Events

On January 12, 2015, Eagle Pharmaceuticals, Inc., or the Company, will present the attached discussion of the Company’s business model, products and product candidates at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, being held on January 12 - 15, 2015.

A copy of the above referenced presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.	Description
99.1	Presentation of the Company dated January 12, 2015

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Eagle Pharmaceuticals, Inc.
Dated: January 12, 2015
	By:	/s/ Scott Tarriff
		Scott Tarriff
		President and Chief Executive Officer

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation of the Company dated January 12, 2015

4

EX-99.1

Exhibit 99.1

January 2015 Scott Tarriff, CEO David Riggs, CFO NASDAQ: EGRX

Forward Looking Statements 2 This presentation contains certain forward-looking information about Eagle Pharmaceuticals that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “strong,” “upcoming,” “prepared” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether the FDA will approve our NDA for our bendamustine product and other pharmaceutical products in development and when such approval might be granted; whether the results of the safety assessment will be accepted by prescribers as evidence of comparative safely benefit; whether we will successfully market our products; our ability to successfully compete with other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; the strength and enforceability of our intellectual property rights; the outcome of pending litigation; general economic conditions; and the other risk factors included in our periodic and interim reports filed with the Securities and Exchange Commission including but not limited to our annual report on form 10-K. Our audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Eagle Pharmaceuticals Nasdaq: EGRX Specialty pharmaceutical company Differentiated forms of branded injectables Revenues from three products Ryanodex (launched Aug. 2014 in MH) Argatroban Diclofenac/misoprostal Significant near-term commercial opportunities Preparing for 2015 launch of Bendamustine RTD On track to file RTU Bivalirudin 2Q:15 Ryanodex label expansion: Exertional heat stroke Long life cycles = significant value Strong & growing IP around differentiating features Orphan drug designations Well capitalized to execute growth strategy

In-Market Products + Attractive Late Stage Portfolio Preclinical Clinical NDA filing Approval In-market Market Opp1 Orphan Drug $99M $43M $75-80M+ $700M+ $700M+ $150M+ $550M $2.7B Bendamustine RTD 30/60 min. admin in 500 mL admixture Bendamustine RTD 10 min. admin in 50 mL admixture Diclofenac/misoprostol (legacy ANDA; generic Arthotec) Ryanodex Exertional Heat Stroke RTU bivalirudin Pemetrexed Argatroban Tentative approval 7/2/14 Positive data reported 11/10/14 1 Source: publicly filed reports with the SEC, independent market research and management’s estimates Ryanodex (dantrolene) Malignant Hyperthermia

Bendamustine RTD Improved formulation of Treanda1 In 500 mL admixture, 30- or 60-minute infusion time (same as Treanda) Tentative approval for NHL received 7/02/14 One patent infringement lawsuit dismissed (‘524), one pending (‘270) ‘270 patent covers lyophilized forms of bendamustine Eagle believes the ‘270 patent is similar to the ‘524 No 30-month stay 1 Treanda® (bendamustine HCl) (Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.) 2 CLL: chronic lymphocytic leukemia 3 NHL: indolent B-cell non-Hodgkin lymphoma

Bendamustine RTD Improved formulation of Treanda1 In 500 mL admixture, 30- or 60-minute infusion time (same as Treanda) Tentative approval for NHL received 7/02/14 One patent infringement lawsuit dismissed (‘524), one pending (‘270) ‘270 patent covers lyophilized forms of bendamustine Eagle believes the ‘270 patent is similar to the ‘524 In 50 mL admixture, 10-minute infusion time Positive clinical data reported 11/10/14 will change ‘how to administer’ section of label ODD granted 7/02/14 for CLL & NHL May afford 7 years exclusivity on approval One patent issued to June 2031, one newly allowed, 6 pending 1 Treanda® (bendamustine HCl) (Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.) 2 CLL: chronic lymphocytic leukemia 3 NHL: indolent B-cell non-Hodgkin lymphoma

Bendamustine RTD in 50mL Admixture Positive Clinical Data Open-label, crossover, randomized, blinded Phase I clinical trial in 81 patients Bioequivalence & safety vs. Treanda Met primary endpoint: bioequivalent to Treanda Met safety endpoints: incidence & profile of AEs (infusion-related & general) comparable to Treanda Positive data will change ‘how to administer’ section of label Pre-NDA meeting occurred December 17th Data and design acceptable Timing of filing to be updated shortly 1 Treanda® (bendamustine HCl) (Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.)

Bendamustine RTD Market Opportunity Treanda sales over $700M Preparing for possible 2015 launch Conversion expected due to multiple benefits of our bendamustine RTD in 50mL admixture with 10 minute infusion time Plan to file for unique J-code 1 12 months ended 9/30/2014 sales of $718M, source: Teva Pharmaceutical press releases dated 2/6/2014 and 10/30/2014

Multiple Benefits of Bendamustine RTD in 50mL Admixture Patient Less chair time: 30 or 60 min. reduced to 10 min. Less volume & issues related to 50mL vs. 500mL admixture Nurse Less nursing time required Medical/Patient 90% reduction in NaCl - renal suppressed population Economic Additional patient treated in the cancer clinic enabled by shorter infusion time

No change to SOC for MH treatment in over 30 years Often fatal if untreated Ryanodex approved July 22, 2014 Optimized formulation Reduces to 5mL (1 vial) vs. 720 mL (12 vials) for old product Breakthrough change Expected to take over market Protected market position 3 patents issued + 1 filed Orphan drug designation for MH (U.S. & Europe) EU regulatory submission to be filed in 4Q:15 Ryanodex® (dantrolene) for Malignant Hyperthermia (MH)

Ryanodex: US Commercial Landscape Ryanodex launched Aug 29, 2014 Small sales force Premium pricing to old formulation Supported by Ryanodex advantages Faster administration Reduced volume Significant reduction of Mannitol (diuretic) Expands addressable market ~$20M $75-80M Ryanodex Premium Pricing Old Product Pricing1 Ryanodex Market Opportunity (Over 2 Years) 1 Branded dantrolene sales for MH 2013

Ryanodex: US Commercial Landscape All US hospitals required to stock dantrolene ~9,000 outlets MHAUS1 recommends a minimum 36 vials = 3 vials Ryanodex Repurchase required every 2 years Ryanodex advantages = unlikely to revert to old 720mL formulation Early conversions include multiple top-tier hospitals 1 Joint Commission; MHAUS: Malignant Hyperthermia Association of the United States

Why Dantrolene? MH Exertional Heat Stroke Ecstasy Overdose Duchenne Europe ROW Initial indication: Malignant Hyperthermia Larger markets + Unmet needs Further opportunity for all indications Malignant Hyperthermia is just the tip of the iceberg Rhabdomyolysis

Ryanodex for EHS: Initial Label Expansion Opportunity Exertional Heat Stroke (EHS) Est. 23,000-38,000 cases/year1 A leading cause of student athlete death (US) & non-combat military deaths Similarities to MH Potential for Ryanodex to be first to market for EHS Orphan drug designation for EHS Potential for 7 years of exclusivity Market estimated at $150M+ Type C meeting with FDA scheduled for March 11th Asking for Saudi September 2015 study to be pivotal 1 Estimate based on 2010 population projections

Enhanced RTU version of the anticoagulant Angiomax1 Brand sales over $580M 2 Two patents issued; third patent filed 1Q:14 NDA submission targeted for 2Q:15 US launch planned as early as 1Q:16 Very strong non-infringement arguments Different from existing ANDA litigation Bivalirudin RTU 1 Angiomax® (bivalirudin) (The Medicines Company) 2 12 months ended 9/30/2014 sales of $584M, source: The Medicines Company press releases dated 2/19/2014 and 10/22/2014

Pemetrexed Liquid version of Alimta1, a powder cytotoxic API indicated for pleural mesothelioma & NSCLC No reconstitution No dilution Less exposure to cytotoxic vapors for healthcare staff $2.7B global market opportunity2 Expect to launch with generics (2017-21) 1 Alimta® (pemetrexed) (Eli Lilly & Co.) 2 FY 2013 Alimta sales, source: Eli Lilly & Co. press release dated 1/30/2014

US Patents Longevity Orphan Drug FDA Action Issued Filed Argatroban 2 1 Sept 2027 In-market Ryanodex (dantrolene): MH 3 1 Jul 2022- Jul 2025 US EU In-market Bendamustine RTD: NHL & CLL 2 3 Jan 2031- Mar 2033 US 500mL Tentative Approval 7/2/14 50mL meeting w. FDA 12/14 Ryanodex: Heat stroke/EHS 1 Feb 2023 US RTU bivalirudin 21 1 Aug 2029- May 2034 Other 2 3 Feb 2027– Dec 2032 TOTAL 12 9 4 Combination Approach for Long Life Cycle 1 Jointly owned by Medicines Co. & Eagle Patents expected to be Orange Book listed & potentially result in 30 month stays + potential long term protection

Achievements Since Jan:14 Near-term Milestones Ryanodex® NDA filed: MH Mar:14 Type C meeting with FDA Mar:15 Patent issued: heat stroke 1Q:14 Initiate clinical study: EHS Sept:15 FDA approval: MH Jul:14 File with EMA: MH 4Q:15 US Launch: MH Aug:14 ODD from EMA: MH Nov:14 Bendamustine Tentative approval (500mL) Jul:14 2nd patent issuance (50mL) 4Q:14 Received ODD (50mL) Jul:14 Launch* 524 patent lawsuit dismissed Nov:14 Positive study data (50mL) Nov:14 Discuss clinical results w. FDA Dec:14 *pending outcome of ongoing discussions RTU Bivalirudin Third patent filed 1Q:14 File NDA 2Q:15 Completed 3 registration batches for NDA 1Q:14 Potential US launch 1Q:16 Other Successful IPO raised $46M net Feb:14 US launch: diclofenac/misoprostol 1Q:15 ANDA approved: diclofenac/misoprostol 3Q:14

Investment Considerations Large market opportunity in injectable products space Revenues from three in-market products Near term product launch opportunities with high margins 3 Orphan Drugs: Ryanodex EHS & MH and bendamustine 50mL admixture Strong IP portfolio to protect market position: 12 patents issued Long life cycle creates significant value opportunity Strong balance sheet with over $36M in cash1 1 As of December 31, 2014

January 2015